IOVA

IOVANCE BIOTHERAPEUTICS, INC.

IOVA · CIK 1425205 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$264M
20182025
Net Income−$391M
20182025
Operating CF−$302M
20182025
Free Cash Flow−$336M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.3B$0.2B$0.0B————$0.0B
Cost of Revenue$0.2B$0.1B$0.0B—————
Gross Profit————————
R&D Expense$0.3B$0.3B$0.3B$0.3B$0.3B$0.2B$0.2B$0.1B
SG&A Expense————————
Operating Income$-0.4B$-0.4B$-0.5B$-0.4B$-0.3B$-0.3B$-0.2B$-0.1B
Net Income$-0.4B$-0.4B$-0.4B$-0.4B$-0.3B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.09$-1.28$-1.89$-2.49$-2.23———
EPS (Diluted)$-1.09$-1.28$-1.89$-2.49$-2.23———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.9B$0.9B$0.8B$0.7B$0.8B$0.8B$0.3B$0.5B
Current Assets$0.4B$0.5B$0.3B$0.5B$0.5B$0.6B$0.3B$0.5B
Cash & Equivalents$0.2B$0.1B$0.1B$0.2B$0.1B$0.1B$0.0B$0.1B
Total Liabilities$0.2B$0.2B$0.2B$0.2B$0.2B$0.1B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Stockholders' Equity$0.7B$0.7B$0.6B$0.5B$0.6B$0.7B$0.3B$0.5B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.4B$-0.4B$-0.3B$-0.2B$-0.2B$-0.2B$-0.1B
Investing Cash Flow$0.0B$-0.1B$-0.2B$0.3B$0.0B$-0.3B$0.1B$-0.4B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.3B$0.4B$0.5B$0.2B$0.2B$0.6B$0.0B$0.4B
← Companies